Crossject SA ALCJ
EURONEXT · France · Health Technology
€1.35-0.03 (-2.17%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May. Shareholders’ equity returned to positive territory at €3.0 million (compared to −€4.9 million as of December 31, 2025), and adjusted net financial debt was more than halved to €7.8 million (from €17.4 million). BARDA revenue totaled €2.5 million (€6.6 million in H1 2025), as H1 2025 saw a concentration of v
The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle LiebschutzA leadership team covering the entire value chain: pharmaceutical development, industrial operations, quality and regulatory affairs, finance and corporateCROSSJECT US strengthens its regulatory leadership with the appointment of David Pudwill as Vice President, Regulatory & Scientific Affairs DIJON, FRANCE, September 25, 2026 – 07h30 (CEST) – CROSSJECT (I
CROSSJECT and BARDA have consolidated the clinical development plan for the pediatric indication of ZEPIZURE®, in alignment with the FDA guidance$4.7 million in additional, non-dilutive funding, to cover the planned activities — total BARDA funding for ZEPIZURE® development now $48.0 millionContract period of performance extended through June 21, 2030 The EUA pathway for the adult indication is unaffected: the scope, content and data package of the EUA dossier remain unchanged DIJON, France — Se
CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group) DIJON, France - February 2, 2026 (7:15 a.m. CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), the specialty pharmaceutical company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology. CROSSJECT is in the advanced stages of developing and registering ZEPIZURE®, an injectable for the treatment of epileptic seizures, and announces the initi
Press release CROSSJECT completes €5 million financing with Vatel Capital DIJON, France – November 14th, 2025 (8.30 PM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company that develops products for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, in the advanced stages of development and registration of ZEPIZURE®, an injectable for the treatment of epileptic seizures, today announces the completion of a €5 million f
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.